Tilray Medical Strengthens Global Medical Cannabis Supply Chain with Approval to Bring Critical EU-GMP Quality Testing In-House, Accelerating Product Release Across Regulated Global Markets
Key Highlights
- ➤INFARMED approved Tilray Medical’s Portugal laboratory for in-house microbiological and chemical/physical testing
- ➤Approval strengthens Cantanhede as a strategic hub for cultivation, production, testing, and exports
- ➤In-house testing could reduce batch-release costs and shorten product-release timelines
- ➤Tilray Medical supplies regulated markets including Germany, the United Kingdom, Poland, and Italy
Expert Statements
Rajnish Ohri, President, International, Tilray Brands
“As regulated medical cannabis markets continue to mature, the companies best positioned to lead will be those that combine pharmaceutical-grade quality, regulatory discipline, and reliable global supply at scale. Tilray has built one of the world’s leading EU-GMP-certified medical cannabis operations, and this approval further strengthens our platform in Portugal by bringing advanced quality testing closer to cultivation and production. It gives us greater speed, control, and flexibility across our international supply chain while reinforcing the infrastructure and technical expertise required to serve patients, physicians, pharmacies, and commercial partners with trusted medical cannabis products in high-standard markets around the world.”
CANTANHEDE, Portugal, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Tilray Medical, a global leader in medical cannabis research, cultivation, production, products and distribution and a division of Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), today announced a key regulatory milestone in Europe: INFARMED, Portugal’s National Authority of Medicines and Health Products, has approved the quality control laboratory at Tilray Medical’s EU-GMP-certified facility in Cantanhede, Portugal, to conduct microbiological and chemical/physical testing in-house. The approval gives Tilray Medical greater command over critical quality testing, accelerates product release capabilities, and strengthens its Portugal facility as a strategic launchpad for pharmaceutical-grade medical cannabis supply across regulated international markets.
With this authorization, Tilray Medical further differentiates its European production platform by embedding advanced testing capabilities directly within its EU-GMP infrastructure. The approval reinforces Cantanhede as a strategic center for cultivation, production, testing, and international supply, and comes as demand for trusted, pharmaceutical-grade medical cannabis continues to grow across regulated markets.
Get started
Create a free account to read the full story.